Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Re 12.52,
I dunno, I’d certainly ask him wtf did he sell $500 million in Spce shares for which tanked the sp.
Another nice rise, slow and steady wins the race.
Stoney40 at 11:40.
Would you be ‘honoured’ if Richard Branson invested in your tiny bio? I know I probably would…
Hi Stoney40. Good post from you. A concern you have of individually tailored treatments is of great importance. We are at a stage whereby targeted kinase inhibitors are reaching a potential way in advance of what was once thought.
We now have 17 years of protection.
Molecules can be tweaked to maximise inhibition in an effort to achieve maximum safety and at the same time effectiveness, i dare say our SKIL played a vital part in this,
I was also intrigued at the level of new information in areas critical to certain targets.
One size does not fit all, and my belief that due to lack selectivity and not paying attention to detail in the areas of qulity control is the reason many inhibitors have fallen by the wayside at great expense to a financially committed pharma.
A new world is dawning with targeted kinase inhibitors especially Tyk 2 ( not the be all and end all on its own)
We will be at the forefront of that I am sure. Attention to detail whilst hard at times will I perceive pay off.
Both SDC1801 and 1802 have a potential to rake in many tens of billions in revenue over the next 17 years.
Of most importance is lives will be saved and the quality of life for many will change for the better too.
Regards
Oh and Richard Branson joined the party this year too, he knows a good thing when he sees one......
https://www.cnbc.com/2021/06/17/gene-testing-firm-23andme-trades-higher-after-branson-spac-merger-.html
GLA
FWIIW my opinion is, should any other party use these patent protected methods for the furtherment of their own compounds, then yes a royalty either as a percentage or one off payment shall be made.
You are looking at X ray crystallography for one example ( whilst not new) is is utilised here to determine the purity of a compound. Even pertaining to the angular degrees to measure peaks at specified angles to confirm compound integrity.
This is my take on it. Sareum had problems with SDC1802 new patent ( as considered too similar to 1801) the god damn mothers would not on repeat applications grant a new patent. However. it would appear that Mr Reader has worked a blinder here in protecting the compound not as the compound per se. but in the manufacture and methods used in quality control ie levels of purity thereof.
In this instance you cannot verify the quality of the compound ( lack of impurities) unless these methods of quality control are provided. It is indeed very complex and precise.
It does also allow further compounds to be made from the molecules which in themselves have patent protection.
In a nutshell we have secured patent protection to allow an extremely high level of quality ( minimalisation of impurities with their associated affects in toxicity and effectiveness ) in the manufacture of our compounds.
Any other party wishing to use this route, or similar to, would be treading on dodgy ground risking patent infringement.
Regards
Interesting question MADD, I know Thoth2 said we’d (I think) patented targeting the actual site a while ago, and our rivals were targeting the site adjacent to it. Way way above my pay grade but good question. If we’ve patented the production method and targeting the actual site, it’s game over for the rest.
GLA
Hi SOG
Thanks for your valued interpretation of the patent. As you say there are hours of reading and further research to be done with it.
As I posted on Sunday, one of the key factors for me is the gene connections and screening for bio markers that can be used to identify susceptibility of a treatment for individuals based either on overexpression or inactive Tyk2 in the patients. This really is next generation medicine and the advent of ‘tailor made’ treatment. I believe this could also apply to SDC-1802 in blood cancers.
This is the work that GSK got into with 23andMe in 2018 (a 4 year collaboration)
https://www.gsk.com/en-gb/media/press-releases/gsk-and-23andme-sign-agreement-to-leverage-genetic-insights-for-the-development-of-novel-medicines/
An extract - which almost matches what is said in the SAR patent:
“Improve target selection to allow safer, more effective ‘precision’ medicines to be discovered. Genetic data can significantly improve our understanding of diseases, their pathways and mechanisms, supporting the design and development of more targeted medicines. Use of genetic data in selecting drug targets can increase both the probability of success in a particular indication and avoid unwanted safety risks”.
And:
“Support identification of patient subgroups that are more likely to respond to targeted treatments. Scale is critical for the detection of genetic effects in smaller subsets of diseases and patients. With over 80% of 23andMe’s customer base consenting to participate in research, their aggregate and de-identified data could help enable the discovery of a significant number of novel associations from a diverse range of people, which would not otherwise be possible”.
GLA
Am I correct in saying that ANY pharmaceutical compound created using this production method, has to pay royalties to Sareum, or is it just for the pharmaceuticals Sareum have created?
Excuse my ignorance btw in these matters.
One more thing I will add and I will then sod off and leave you all in peace. This protects SDC1801 and SDC1802 compounds. The door is now well and truly opened to 'on licensing'. Patent protection for 17 years of Sareums compounds with the added bonus of royalties should another party use this method in the manufacture and quality control of their own products.
Regards
Before offers are made, in whichever form, the period of patent protection provided to its invention ( in this case the manufacture and quality control of its compounds) needs to be realised and confirmed. A very major milestone achieved.
Regards
to 6.94 but now being dragged down again on comp. small volume presumably so that MM's mates can get in before news announcement whatever it may be.